BR112021021996A2 - Métodos para administração de imunoterapia com receptores de antígeno quimérico - Google Patents
Métodos para administração de imunoterapia com receptores de antígeno quiméricoInfo
- Publication number
- BR112021021996A2 BR112021021996A2 BR112021021996A BR112021021996A BR112021021996A2 BR 112021021996 A2 BR112021021996 A2 BR 112021021996A2 BR 112021021996 A BR112021021996 A BR 112021021996A BR 112021021996 A BR112021021996 A BR 112021021996A BR 112021021996 A2 BR112021021996 A2 BR 112021021996A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- chimeric antigen
- cell lymphoma
- antigen receptors
- immunotherapy
- Prior art date
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title abstract 4
- 238000009169 immunotherapy Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 208000003950 B-cell lymphoma Diseases 0.000 abstract 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 abstract 1
- 206010036711 Primary mediastinal large B-cell lymphomas Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000002659 cell therapy Methods 0.000 abstract 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 abstract 1
- 201000003444 follicular lymphoma Diseases 0.000 abstract 1
- 238000001802 infusion Methods 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 238000009121 systemic therapy Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Abstract
métodos para administração de imunoterapia com receptores de antígeno quimérico. a revelação fornece células compreendendo imunoterapia com células t autólogas geneticamente modificadas para receptor de antígeno quimérico (car) direcionadas a cd19 para o tratamento de, por exemplo, linfoma de grandes células b recidivante ou refratário, após duas ou mais linhas de terapia sistêmica, inclusive linfoma difuso de grandes células b (ldgcb) não especificado de outro modo, linfoma primário de grandes células b do mediastino, linfoma de grandes células b de alto grau, e ldgcb decorrente de linfoma folicular. alguns aspectos da revelação se referem a métodos para tratamento e monitoramento após a infusão de terapia com células t aqui fornecida.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962843190P | 2019-05-03 | 2019-05-03 | |
US201962855828P | 2019-05-31 | 2019-05-31 | |
US201962868262P | 2019-06-28 | 2019-06-28 | |
US201962931669P | 2019-11-06 | 2019-11-06 | |
US201962944903P | 2019-12-06 | 2019-12-06 | |
PCT/US2020/031231 WO2020227177A1 (en) | 2019-05-03 | 2020-05-03 | Methods of administering chimeric antigen receptor immunotherapy |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021021996A2 true BR112021021996A2 (pt) | 2022-01-11 |
Family
ID=73050885
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021021996A BR112021021996A2 (pt) | 2019-05-03 | 2020-05-03 | Métodos para administração de imunoterapia com receptores de antígeno quimérico |
Country Status (13)
Country | Link |
---|---|
US (2) | US20200384027A1 (pt) |
EP (2) | EP3962490A4 (pt) |
JP (1) | JP2022532865A (pt) |
KR (1) | KR20220005075A (pt) |
CN (1) | CN114206346A (pt) |
AU (1) | AU2020267378A1 (pt) |
BR (1) | BR112021021996A2 (pt) |
CA (1) | CA3138707A1 (pt) |
IL (1) | IL287533A (pt) |
MX (1) | MX2021013394A (pt) |
SG (1) | SG11202112123RA (pt) |
TW (1) | TW202108150A (pt) |
WO (1) | WO2020227177A1 (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022117799A2 (en) * | 2020-12-04 | 2022-06-09 | Morphosys Ag | Anti-cd19 combination therapy |
WO2022137186A1 (en) * | 2020-12-23 | 2022-06-30 | Crispr Therapeutics Ag | Cancer treatment using cd38 inhibitor and/or lenalidomide and t-cells expressing a chimeric antigen receptor |
CN117396607A (zh) | 2020-12-30 | 2024-01-12 | 阿劳诺斯治疗公司 | 包含多顺反子表达盒的重组载体及其使用方法 |
CN113406334A (zh) * | 2021-06-02 | 2021-09-17 | 浙江省人民医院 | 一种dlbcl相关的生物标记组合物及其应用、dlbcl预后的效果预测模型 |
TW202313665A (zh) * | 2021-07-30 | 2023-04-01 | 美商凱特製藥公司 | 細胞療法誘導之毒性的監測及管理 |
CN113786490A (zh) * | 2021-09-14 | 2021-12-14 | 华中科技大学同济医学院附属协和医院 | 能调控巨噬细胞表观遗传的制剂用于制备治疗噬血细胞综合征药物的应用 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5728388A (en) | 1989-10-03 | 1998-03-17 | Terman; David S. | Method of cancer treatment |
US6319494B1 (en) | 1990-12-14 | 2001-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
WO1994009138A1 (en) | 1992-10-20 | 1994-04-28 | Cetus Oncology Corporation | Interleukin-6 receptor antagonists |
US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
US6406699B1 (en) | 1999-10-05 | 2002-06-18 | Gary W. Wood | Composition and method of cancer antigen immunotherapy |
US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
ATE373078T1 (de) | 2000-02-24 | 2007-09-15 | Xcyte Therapies Inc | Gleichzeitige stimulation und konzentration von zellen |
GB0700058D0 (en) | 2007-01-03 | 2007-02-07 | Scancell Aps | Anti-tumor vaccine based on normal cells |
TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
TR201808019T4 (tr) * | 2010-10-27 | 2018-06-21 | Amgen Res Munich Gmbh | Dlbcl tedavisi için araçlar ve yöntemler. |
JP5947311B2 (ja) | 2010-12-09 | 2016-07-06 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 癌を治療するためのキメラ抗原受容体改変t細胞の使用 |
US9402865B2 (en) | 2011-01-18 | 2016-08-02 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cancer |
MX359513B (es) | 2011-03-23 | 2018-10-01 | Hutchinson Fred Cancer Res | Metodo y composiciones para inmunoterapia celular. |
EP2532740A1 (en) | 2011-06-11 | 2012-12-12 | Michael Schmück | Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy |
US10421960B2 (en) | 2011-09-16 | 2019-09-24 | The Trustees Of The University Of Pennsylvania | RNA engineered T cells for the treatment of cancer |
US10117896B2 (en) | 2012-10-05 | 2018-11-06 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
EP3102609A4 (en) | 2014-02-04 | 2017-08-23 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Methods for producing autologous t cells useful to treat b cell malignancies and other cancers and compositions thereof |
EP3851110A1 (en) | 2015-05-28 | 2021-07-21 | Kite Pharma, Inc. | Methods of conditioning patients for t cell therapy |
WO2017070395A1 (en) | 2015-10-20 | 2017-04-27 | Kite Pharma, Inc. | Methods of preparing t cells for t cell therapy |
CN108495651A (zh) | 2015-12-17 | 2018-09-04 | 诺华股份有限公司 | 抗pd-1的抗体分子及其用途 |
CN110461315A (zh) * | 2016-07-15 | 2019-11-15 | 诺华股份有限公司 | 使用与激酶抑制剂组合的嵌合抗原受体治疗和预防细胞因子释放综合征 |
JOP20180042A1 (ar) * | 2017-04-24 | 2019-01-30 | Kite Pharma Inc | نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام |
MX2019014268A (es) * | 2017-06-02 | 2020-08-03 | Juno Therapeutics Inc | Artículos de manufactura y métodos para tratamiento usando terapia celular adoptiva. |
US11673962B2 (en) * | 2017-10-02 | 2023-06-13 | Humanigen, Inc. | Method of increasing the efficacy of CAR-T immunotherapy using lenzilumab |
SG11202003380TA (en) * | 2017-10-18 | 2020-05-28 | Kite Pharma Inc | Methods of administering chimeric antigen receptor immunotherapy |
-
2020
- 2020-05-03 EP EP20801592.5A patent/EP3962490A4/en not_active Withdrawn
- 2020-05-03 TW TW109114736A patent/TW202108150A/zh unknown
- 2020-05-03 CA CA3138707A patent/CA3138707A1/en active Pending
- 2020-05-03 BR BR112021021996A patent/BR112021021996A2/pt unknown
- 2020-05-03 CN CN202080043985.XA patent/CN114206346A/zh active Pending
- 2020-05-03 SG SG11202112123RA patent/SG11202112123RA/en unknown
- 2020-05-03 MX MX2021013394A patent/MX2021013394A/es unknown
- 2020-05-03 JP JP2021564704A patent/JP2022532865A/ja active Pending
- 2020-05-03 AU AU2020267378A patent/AU2020267378A1/en active Pending
- 2020-05-03 EP EP23186520.5A patent/EP4249075A3/en active Pending
- 2020-05-03 US US16/865,369 patent/US20200384027A1/en not_active Abandoned
- 2020-05-03 WO PCT/US2020/031231 patent/WO2020227177A1/en unknown
- 2020-05-03 KR KR1020217039585A patent/KR20220005075A/ko active Search and Examination
-
2021
- 2021-10-24 IL IL287533A patent/IL287533A/en unknown
-
2023
- 2023-02-10 US US18/167,725 patent/US20230270785A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3962490A4 (en) | 2023-01-25 |
AU2020267378A1 (en) | 2021-11-25 |
IL287533A (en) | 2021-12-01 |
CN114206346A (zh) | 2022-03-18 |
EP4249075A2 (en) | 2023-09-27 |
SG11202112123RA (en) | 2021-11-29 |
CA3138707A1 (en) | 2020-11-12 |
MX2021013394A (es) | 2022-01-04 |
US20200384027A1 (en) | 2020-12-10 |
WO2020227177A1 (en) | 2020-11-12 |
US20230270785A1 (en) | 2023-08-31 |
KR20220005075A (ko) | 2022-01-12 |
EP4249075A3 (en) | 2023-11-08 |
JP2022532865A (ja) | 2022-07-20 |
TW202108150A (zh) | 2021-03-01 |
EP3962490A1 (en) | 2022-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112021021996A2 (pt) | Métodos para administração de imunoterapia com receptores de antígeno quimérico | |
Versteven et al. | Dendritic cells and programmed death-1 blockade: a joint venture to combat cancer | |
Spranger et al. | Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment | |
Yamauchi et al. | CX3CR1–CD8+ T cells are critical in antitumor efficacy but functionally suppressed in the tumor microenvironment | |
AU2018275894A1 (en) | Articles of manufacture and methods for treatment using adoptive cell therapy | |
CO2020004804A2 (es) | Métodos de administración de una inmunoterapia con receptores de antígenos quiméricos | |
MX2020001358A (es) | Celulas t que redirigen el receptor del antigeno quimerico especifico cd123 y metodos de su uso. | |
MX2019006955A (es) | Terapia de combinacion con agonistas de 4-1bb orientados (cd137). | |
WO2020113194A3 (en) | Methods for treatment using adoptive cell therapy | |
EP4289944A3 (en) | Method for preparing genetically-modified t cells which express chimeric antigen receptor | |
WO2020092848A3 (en) | Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen | |
MX2020008336A (es) | Dominios variables de anticuerpos que se dirigen al receptor nkg2d. | |
AR111360A1 (es) | Tratamiento usando células t de receptor quimérico incorporando células t polifuncionales optimizadas | |
MX2021002190A (es) | Estrategia de dosificacion que mitiga el sindrome de liberacion de citoquinas para los anticuerpos biespecificos cd3/cd20. | |
MX2021011816A (es) | Metodos para produccion de celulas car-nk y uso de las mismas. | |
AR116048A1 (es) | Composiciones y métodos para reprogramar receptores de células t (tcr) usando proteínas de fusión | |
CR20200361A (es) | Biomarker predictive of tumour infiltrating lymphocyte therapy and uses thereof | |
WO2019232409A9 (en) | Methods for genome editing and activation of cells | |
BR112022003852A2 (pt) | Métodos de preparação de células t para terapia de células t | |
MX2021013608A (es) | Composiciones y métodos de fabricacion de celulas t. | |
MX2022005815A (es) | Terapia para neoplasias malignas de celulas hematopoyeticas utilizando linfocitos t modificados geneticamente que se dirigen a cd70. | |
CR20220027A (es) | Terapia con linfocitos de infiltración tumoral y sus usos | |
BR112021017365A2 (pt) | Receptores de citocina quiméricos constitutivamente ativos | |
MX2020007543A (es) | Metodos para administrar inmunoterapia de receptor de antigeno quimerico en combinacion con agonista 4-1bb. | |
WO2020113188A3 (en) | Methods for dosing and treatment of b cell malignancies in adoptive cell therapy |